# Coadministration of Measles-rubella and Rotavirus Vaccines

> **NCT01700621** · PHASE4 · COMPLETED · sponsor: **PATH** · enrollment: 482 (actual)

## Conditions studied

- Measles Antibody Seroconversion
- Rubella Antibody Seroconversion
- Rotavirus Geometric Mean Titer (GMT)
- Rotavirus Immunoglobulin A (IgA) Seropositivity

## Interventions

- **BIOLOGICAL:** Rotarix vaccine
- **BIOLOGICAL:** measles-rubella vaccine

## Key facts

- **NCT ID:** NCT01700621
- **Lead sponsor:** PATH
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01
- **Primary completion:** 2013-09
- **Final completion:** 2013-09
- **Target enrollment:** 482 (ACTUAL)
- **Last updated:** 2019-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01700621

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01700621, "Coadministration of Measles-rubella and Rotavirus Vaccines". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01700621. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*